Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of Ervogastat in Healthy, Overweight, and Obese Adults
NCT03230383Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of ervogastat in Nonalcoholic steatohepatitis (NASH) (7 cohorts), sponsored by Pfizer. Primary endpoints: Number of subjects with adverse events, Number of subjects with laboratory tests findings of potential clinical importance and 2 more. Started Aug 2017; status: completed.
02
Drugs
ervogastat
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03230383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230383.